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Background: In recent years, laparoscopic sleeve gastrectomy (LSG) has become one of the most 
commonly used primary bariatric procedures for morbid obesity. While laparoscopic Roux-en-Y gastric 
bypass (LRYGB) has well documented positive clinical influence on type 2 diabetes, the role of LSG in 
diabetes treatment is debatable. The main aim of this study is to present our early experience in LSG as a 
method of bariatric treatment in patients with type 2 diabetes or abnormalities in glucose homeostasis. 
Methods: Prospectively collected data of patients operated for morbid obesity at the 2nd Department of 
Surgery. The study was designed to assess the influence of LSG on type 2 diabetes and glucose homeostasis. 
The primary endpoint was the diabetes type 2 remission. Secondary endpoint was the change of glucose 
metabolism parameters after LSG. Patients were assessed preoperatively and allocated to two groups: 
group 1—with any preoperative abnormalities in glucose homeostasis (prediabetes, diabetes) and group 2—
with non-elevated fasting glucose level. During follow-up (6 months after surgery) all glucose homeostasis 
parameters were analyzed again. One hundred and thirty-six patients after LSG were enrolled in the study 
(90 females, 46 males; mean age 40.5±9.9 years). Preoperative abnormalities in glucose homeostasis were 
confirmed in 64 (47%) patients. Twenty (15%) patients in this group had diabetes. 
Results: We observed significant reduction of body mass index (BMI) after surgery. Mean percent of 
EBMIL for all groups after 6 months from surgery was 59.90% (46.75–69.28%). There were no full 
remissions after surgery in patients with preoperative diabetes. We found significant improvement in 
biochemical markers of glucose homeostasis. We observed significant reduction of HbA1c% after surgery in 
both groups. The level of postoperative HbA1c% was related to BMI loss after surgery. 
Conclusions: LSG leads to significant improvement in biochemical glucose homeostasis and can be 
considered as a method of treatment in morbidly obese patients with glucose metabolism abnormalities. LSG 
as a method of treatment for patients with clinical type 2 diabetes still needs some further observation.
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Introduction
The main answer to the worldwide obesity epidemic is the 
increase in the number of performed bariatric procedures. 
Type 2 diabetes and glucose metabolism abnormalities are 
one the most important effects of morbid obesity which lead 
to severe and chronic reduction in quality of health. High 
effectiveness of bariatric therapy for weight reduction and 
treatment of comorbidities has been proven in numerous 
studies (1). But it is yet still unclear which bariatric 
procedure should be chosen for diabetic patients in order to 
achieve the best results in diabetes remission (2). 
In recent years, laparoscopic sleeve gastrectomy (LSG) 
has become one of the most commonly used primary 
bariatric procedure for morbid obesity (3,4). Numerous 
authors strive to prove that effect of LSG on type 2 diabetes 
treatment is as good as laparoscopic Roux-en-Y gastric 
bypass (LRYGB), which was known as a “gold standard” 
for diabetic patients. Potential mechanisms of diabetes 
remission and improvement in glucose homeostasis after 
LSG are the main topic of recent studies, yet its results 
are still unclear (5). While LRYGB has well documented 
positive clinical influence on type 2 diabetes, the role of 
LSG in diabetes treatment is debatable. Many studies show 
great biochemical results. Although this should induce 
diabetes remission, the clinical long-term results are not so 
optimistic. 
Aim of study
The main aim of this study is to present our early experience 
in LSG as a method of bariatric treatment in patients with 
type 2 diabetes or abnormalities in glucose homeostasis. 
The secondary aim of our study is identification of potential 
preoperative predictors of diabetes remission and glucose 
homeostasis improvement.
Methods
Prospectively collected data of patients operated for morbid 
obesity at the 2nd Department of Surgery, Jagiellonian 
University Medical College were analyzed. Guidelines 
of the Metabolic and Bariatric Surgery Section of the 
Polish Surgical Society were used as criteria for surgical 
treatment, i.e., body mass index (BMI) ≥35 kg/m2 with 
obesity comorbidities, or BMI ≥40 kg/m2, with or without 
comorbidities. All patients included in the study underwent 
LSG. The study was designed to assess the influence of 
LSG on type 2 diabetes and glucose homeostasis. The 
primary endpoint was the diabetes type 2 remission, which 
was described as glycosylated hemoglobin—HbA1c <6% 
(42 mmol/mol) without the use of diabetes medications. 
Secondary endpoint was the change of glucose metabolism 
parameters after LSG. Patients were assessed preoperatively 
and allocated to two groups: group 1—with any preoperative 
abnormalities in glucose homeostasis (prediabetes, diabetes) 
and group 2—with non-elevated fasting glucose level. To 
identify potential preoperative factors which can predict 
results of metabolic outcome, typical glucose homeostasis 
parameters were analyzed: fasting glucose level, insulin, 
proinsulin,  C-peptide,  HOMA-IR, HOMA-B and 
HbA1c%. During follow-up (6 months after surgery) all 
glucose homeostasis parameters were analyzed again. 
Statistical analysis was performed using STATISTICA 
10.0 PL. Data are presented as median values with inter-
quartile range. Chi-square exact Fisher test, Pearson and 
Yates tests were used to compare of qualitative data. The 
t-test and Mann-Whitney, Wilcoxon, Cochrane-Cox tests 
analyzed quantitative differences between groups. Data 
were found statistically significant with P value of 0.05.
Ethical statement: the study was approved by the ethics 
review committee of the Jagiellonian University (approval 
number KBET/156/B/2011) and written informed consent 
was obtained from all patients.
Material
Two hundred and thirty-six patients underwent laparoscopic 
bariatric procedures at 2nd Department of General Surgery, 
Jagiellonian University Medical College between 2014 
and 2016. One hundred and thirty-six patients after LSG 
were enrolled in the study (90 females, 46 males; mean 
age 40.5±9.9 years). Preoperative abnormalities in glucose 
homeostasis were confirmed in 64 (47%) patients [42 
females, 22 males; mean age 47 (35.5–54) years]. Twenty 
(15%) patients in this group had diabetes and 44 (32%) 
had prediabetes defined as abnormal level of glucose 
homeostasis parameters. Seventy-two (53%) patients had 
normal fasting glucose level [48 females, 24 males; mean age 
34 (27.5–43.5) years]. Median preoperative BMI in group 
with preoperative abnormalities in glucose homeostasis and 
without was respectively 46 (42.95–51.9) and 44.85 (40.9–
48.2) kg/m2. Typical comorbidities were more common in 
the group of patients with preoperative abnormalities in 
glucose homeostasis. Table 1 presents groups characteristics. 
Patients’ flow through the study is illustrated in Figure 1.
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Table 1 Patients characteristics
Parameter
Preoperative abnormalities in glucose 
homeostasis
Non-elevated fasting glucose 
level
P
Gender [%] 0.898
Female 42 [66] 48 [67]
Male 22 [34] 24 [33]
Median age (IQR), years 47.0 (35.5–54.0) 34.0 (27.5–43.5) <0.001
Median preoperative BMI (IQR), kg/m2 46.00 (42.95–51.90) 44.85 (40.90–48.20) 0.020
Median obesity duration [IQR], years 15 [7–29] 15 [10–22] 0.552
Operative time, mean ± SD, min 102.5 (80.0–130.0) 120.0 (90.0–147.0) 0.133
Smoking [%] 42 [66] 28 [40] 0.003
Median smoking duration (IQR), package years 2.0 (0–15.0) 0 (0–2.8) 0.001
Median no-smoking period (IQR), years 0 (0–3) 0 (0–4) 0.910
Arterial hypertension [%] 44 [69] 40 [56] 0.114
Median arterial hypertension duration (IQR), years 2.5 (0–10.0) 0.1 (0–5.0) 0.025
Coronary artery disease [%] 10 [16] 0 [0] –
Myocardial infarction [%] 4 [6] 2 [3] 0.571
Obstructive sleep apnea [%] 10 [17] 2 [3] 0.019
Hypercholesterolemia [%] 22 [34] 20 [28] 0.406
Mean hypercholesterolemia duration (IQR), years 0 (0–1) 0 (0–0) 0.057
NAFLD [%] 52 [81] 62 [86] 0.442
Physical activity [%] 0.189
Mild physical activity 12 [21] 8 [15]
Moderate physical activity 24 [43] 34 [63]
Severe physical activity 18 [32] 10 [19]
Results
We observed significant reduction of BMI after surgery 
in the group with abnormalities in glucose homeostasis 
[46 (42.95–51.9) to 33 (29.4–38.9) kg/m2]. Comparable 
results we found in the group with non-elevated fasting 
glucose level [44.85 (40.9–48.2) to 33.3 (31.4–37.2) kg/m2]. 
Mean percent of EBMIL for all groups after 6 months from 
surgery was 59.90% (46.75–69.28%). 
Unfortunately there were no full remissions after surgery 
in patients with preoperative diabetes. Every patients 
with preoperative insulin treatment remained on insulin, 
however the dose of insulin decreased. Of 60 (44%) patients 
who were preoperatively taking oral diabetic medications, 
only 36 (26%) need them during follow up. The number 
of patients with poor glycemic control decreased from 14 
(70%) to 8 (40%) (Table 2). 
We found significant improvement in biochemical 
markers of glucose homeostasis. Number of patients with 
prediabetes significantly decreased from 44 (32.35%) to 
16 (11.76%), P<0.001. Insulin resistance (HOMA-IR) in 
both groups (with and without abnormalities in glucose 
homeostasis) decreased significantly after surgery from 
6.62% (5.58–8.41%) and 5.30% (3.99–8.47%). Median 
insulin level dropped from baseline 30.37 (24.33–34.75) to 
15.91 (11.02–24.46) mU/mL in first group and from 24.59 
(19.54–41.04) to 17.33 (13.95–22.04) mU/mL in the second. 
Proinsulin level decreased from 3.40 (2.30–4.77), 3.18 (2.37–
5.14) to 1.66 (1.45–2.77), 2.18 (1.28–2.53) pmol/L respectively. 
There were no significant changes in postoperative levels 
of C-peptide. Medium level of HbA1c% before surgery 
in the group with preoperative abnormalities in glucose 
homeostasis was 5.95% (5.7–6.6%) and 5.35% (5.1–5.5%) 
in the group with non-elevated fasting glucose level. We 
observed significant reduction of HbA1c% after surgery 
in both groups to 5.6% (5.5–5.7%) and 5.15% (4.9–5.2%) 
(Table 3). The level of postoperative HbA1c% was related to 
BMI loss after surgery (Figure 2). 
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A univariate logistic regression analysis showed that 
preoperative age (OR, 9.92; 95% CI, 0.87–0.97; P=0.003), 
fasting glucose level (OR, 0.5; 95% CI, 0.29–0.87; P=0.013), 
HbA1c% (OR, 0.19; 95% CI, 0.06–0.61; P=0.004), total 
cholesterol level (OR, 2.2; 95% CI, 1.24–3.91; P=0.007) and 
LDL (OR, 2.57; 95% CI, 1.28–5.16; P=0.006) were related 
with postoperative diabetes remission and improvement of 
glucose metabolism (Table 4). 
Discussion
LRYGB and LSG are currently the most common bariatric 
surgeries in Poland (6). The role of bariatric surgery 
in treatment of morbid obesity is well established in 
our country. The effect of bariatric surgeries on weight 
reduction is important as well as its impact on comorbidities, 
especially type 2 diabetes. In the age of bariatric surgery, 
type 2 diabetes can be viewed as a curable disease. Bariatric 
surgery has been confirmed to be beneficial in remission of 
abnormalities in glucose homeostasis (7). Type 2 diabetes is 
an indication for bariatric surgery if patient’s BMI exceeds 
35 kg/m2. Patients with BMI >30 and <35 kg/m2 may be 
considered for metabolic surgery on an individual basis (8,9). 
Unfortunately, no surgical guidelines for bariatric treatment 
or any statements of international diabetes organization 
define what kind of surgery would best for diabetic patients 
with morbid obesity (9-11). 
Due to very good long-term effects  on weight 
Figure 1 Flow chart. LSG, laparoscopic sleeve gastrectomy.
Table 2 Remission of abnormalities in glucose homeostasis
Parameter Preoperative (%) 6 months after surgery (%) P
Prediabetes 44 (32.35) 16 (11.76) <0.001
Diabetes mellitus 20 (14.71) 20 (14.71) –
Poor glycemic control 14 (70.00) 8 (40.00) 0.024
Insulin resistance 4 (20.00) 4 (20.00) –
Oral diabetic medications 60 (44.00) 36 (26.00) 0.002
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reduction and remarkable resolution of comorbidities and 
improvements in glucose homeostasis, LRYGB formerly 
regarded as absorptive procedure became a standard 
procedure. However it is a difficult procedure, with 
numerous early and late complications and high risk of 
malnutrition in the future. For this reason many authors try 
to use different techniques to treat diabetic patients. LSG 
is technically easier, and the newest data suggest occurrence 
of some important metabolic changes after operation. 
Nowadays LSG is no more defined as an only restrictive 
procedure (2). 
In the literature we can find confusing data about 
weight loss results after LRYGB and LSG. In some articles 
authors present higher percent of EWL after LRYGB. 
Our observation revealed that the weight reduction after 
both procedures is similar (12). In our study percent of 
EBMIL after LSG, measured 6 months after surgery, was 
59.90% (46.75–69.28%) and it was comparable to others 
Figure 2 Relation between BMI and HbA1c%. BMI, body mass 
index.
Table 3 Analysis of glucose metabolism related parameters
Parameter
Preoperative abnormalities in glucose homeostasis 
(n=64)
Non-elevated fasting glucose level (n=72)
Preoperative 6 months after surgery P Preoperative 6 months after surgery P
Median HOMA-IR (IQR), (%) 6.62 (5.58–8.41) 3.71 (2.79–5.17) <0.001 5.30 (3.99–8.47) 3.34 (2.75–5.56) <0.001
Median HOMA-B (IQR), (%) 319.92  
(187.52–478.06)
275.95  
(160.66–345.86)
0.804 363.15  
(263.97–603.61)
326.59  
(286.33–433.28)
0.166
Median insulin (IQR), mU/mL 30.37 (24.33–34.75) 15.91 (11.02–24.46) <0.001 24.59 (19.54–41.04) 17.33 (13.95–22.04) <0.001
Median proinsulin (IQR), pmol/L 3.40 (2.30–4.77) 1.66 (1.45–2.77) <0.001 3.18 (2.37–5.14) 2.18 (1.28–2.53) <0.001
Median C-peptide (IQR), nmol/L 6.75 (5.22–8.63) 7.08 (4.00–8.13) 0.139 6.36 (4.79–8.13) 6.01 (4.34–9.18) 0.545
Median fasting glucose level 
(IQR), mmol/L 
5.64 (4.92–6.60) 4.94 (4.50–5.21) <0.001 4.89 (4.50–5.24) 4.66 (4.41–4.89) 0.002
Median HbA1c (IQR), (%) 5.95 (5.70–6.60) 5.6 (5.50–5.70) <0.001 5.35 (5.10–5.50) 5.15 (4.90–5.20) <0.001
Total cholesterol, mean ± SD, 
mmol/L
5.13±1.11 5.21±1.08 0.111 5.09±0.95 5.08±1.06 0.105
Median HDL (IQR), mmol/L 1.15 (1.00–1.33) 1.11 (1.01–1.50) 0.002 1.10 (1.00–1.30) 1.20 (1.10–1.42) 0.003
Median LDL (IQR), mmol/L 2.95 (2.35–3.50) 3.20 (2.50–4.20) 0.884 3.00 (2.40–3.40) 3.35 (2.40–3.80) 0.172
Median triglycerides (IQR), 
mmol/L
1.89 (1.41–2.41) 1.42 (1.06–1.67) <0.001 1.77 (1.20–2.50) 1.05 (0.83–1.32) <0.001
Median BMI (IQR), kg/m2 46.00 (42.95–51.90) 33.00 (29.40–38.90) <0.001 44.85 (40.90–48.20) 33.30 (31.40–37.20) <0.001
Median WHR (IQR), (%) 0.93 (0.88–1.04) 0.89 (0.86–0.96) 0.001 0.91 (0.84–0.97) 0.86 (0.81–0.95) <0.001
Median EBMIL (IQR), (%) – 59.14 (46.84–73.29) – – 59.90 (46.75–69.28) –
Median ejection fraction (IQR), (%) 66.00 (61.00–71.00) 64.00 (56.00–71.00) 0.094 66.00 (61.00–71.00) 69.50 (66.00–73.00) 0.082
BMI, body mass index.
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Table 4 Uni- and multivariate logistic regression analyses of parameters affecting remission of abnormalities in glucose homeostasis
Parameter
Univariate logistic regression Multivariate logistic regression
OR 95% CI P OR 95% CI P
Gender (female vs. male) 2.93 0.94–9.16 0.059
Age (years) 0.92 0.87–0.97 0.003 0.95 0.89–1.02 0.166
Obesity duration (years) 1.01 0.97–1.05 0.662
Smoking (yes vs. no) 0.51 0.18–1.49 0.210
Smoking duration (years) 1.00 0.96–1.04 0.938
No-smoking period (years) 0.90 0.79–1.02 0.100
Arterial hypertension (yes vs. no) 0.38 0.13–1.15 0.081
Arterial hypertension duration (yes vs. no) 0.94 0.87–1.02 0.106
Obstructive sleep apnea (yes vs. no) 0.10 0.01–10.30 0.340
Hypercholesterolemia (yes vs. no) 0.34 0.11–1.06 0.059
Hypercholesterolemia duration, mean ± SD (years) 0.93 0.82–1.05 0.246
NAFLD (yes vs. no) 5.00 0.97–25.90 0.050
Physical activity (severe vs. moderate vs. mild) 0.73 0.38–1.42 0.344
HOMA-IR 0.87 0.74–1.02 0.069
HOMA-B 1.00 0.99–1.00 0.153
Insulin (1 mU/mL) 0.96 0.90–1.01 0.107
Proinsulin (1 pmol/L) 0.85 0.65–1.11 0.208
C-peptide (1 nmol/L) 0.98 0.79–1.22 0.859
Fasting glucose level (1 mmol/L) 0.50 0.29–0.87 0.013
HbA1c (1%) 0.19 0.06–0.61 0.004 0.29 0.07–1.11 0.065
Total cholesterol (1 mmol/L) 2.20 1.24–3.91 0.007
HDL (1 mmol/L) 1.56 0.19–12.65 0.671
LDL (1 mmol/L) 2.57 1.28–5.16 0.006 3.03 1.21–7.59 0.016
Triglycerides (1 mmol/L) 0.89 0.50–1.58 0.689
BMI on the day of surgery 1.00 0.92–1.08 0.933
WHR on the day of surgery 0.02 <0.01–5.51 0.155
EBMIL 1.03 0.98–1.08 0.182
Ejection fraction (1%) 0.98 0.92–1.04 0.424
BMI, body mass index.
authors (13,14). 
In opposition to LRYGB, mechanisms of diabetes 
remission after LSG are not well-defined. The GLP-1 play 
the key-role in changes of glucose metabolism and it is 
responsible for improvement of glucose homeostasis after 
LRYGB. After LSG the level of GLP-1 rises as well, thus it 
has been suggested to contribute to potential improvements 
in diabetes remission (15). In our previous studies we 
noticed the same relations between gut hormones after 
LSG (16). 
Numerous authors present satisfactory biochemical 
results which should be related with diabetes remission. 
Unfortunately long-term clinical observations are not so 
encouraging. Similarly, in our study after 6 months from 
the surgery we noticed significant remission of biochemical 
abnormalities of glucose homeostasis, however we did not 
cure diabetes. Twenty patients with type 2 diabetes before 
surgery still need medical treatment for glycemic control. 
Jammu and Sharma in their group described remission of 
type 2 diabetes in 13 of 23 patients (17). Sixty-seven percent 
of diabetes remission after LSG was presented in the 
study of Milone, who compared it with results after mini 
gastric bypass (18). All patients who preoperatively needed 
insulin still need it, but at a lower dose. All patients reduced 
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oral diabetic medications. We noticed improvement in 
biochemical glucose homeostasis, which was described as 
significant changes of HOMA-IR, level of insulin, C-peptide 
and HbA1c% after 6 months. Despite that there were no 
cases of complete remission of diabetes. Similar results and 
very rare diabetes remission was presented by Aminian (19). 
The most important issue in assessment of metabolic 
effects of bariatric surgery is the criteria for diabetes 
remission. This creates space for potential biases. It can 
explain the differences found in the literature.
Nevertheless even if patient did not meet the clinical 
criteria of complete remission of type 2 diabetes, the most 
important metabolic profit after surgery is improvement 
in glycemic control. It can be noticed in the level of 
HbA1c% after surgery, which reduced significantly. Our 
observation refers to both, group with abnormalities in 
glucose homeostasis and the group with non-elevated 
fasting glucose level. Vigneshwaran et al. present similar 
observations. In their study level of HbA1c% decreased 
from (8.7±1.6)% to (6.7±1.5)% (20). Interestingly the level 
of HbA1c% was correlated to percent of EBMIL in contrast 
to results presented in the Milone study (18).
The preoperative information about potential predictors 
of postoperative glycemic abnormalities remission can lead 
to improvement of long-term effects. In “ABCD score” 
we can find some potential factors (age, BMI, C-peptide, 
diabetes duration) which can be useful to predict diabetes 
remission after bariatric surgery (21). In our study we tried 
to confirm this relationship and identify some new factors, 
which can be related with better or worse metabolic answer 
after LSG. We noticed that only age, fasting glucose level, 
HbA1c%, total cholesterol level and LDL level were 
statistically important for remission of abnormalities in 
glucose homeostasis. Age and HbA1c% seem to be the most 
important factors. Similar to our observation, Milone et al. 
considered HbA1c% as a negative predictor of diabetes 
remission (18). In the study of Hamza, chance for diabetes 
remission was reduced by 20% with each additional 12 years 
of age (22). Older age and worse glycemic control, defined 
as a higher level of HbA1c%, are the negative predictors for 
diabetes remission. In patients with such condition LRYGB 
should be recommended.
Conclusions
LSG leads to significant improvement in biochemical 
glucose homeostasis and can be considered as a method 
of treatment in morbidly obese patients with glucose 
metabolism abnormalities. LSG as a method of treatment 
for patients with clinical type 2 diabetes still needs 
some further observation. In elderly patients with 
poorly compensated type 2 diabetes LRYGB should be 
recommended.
Long term observat ions  f rom double-b l inded 
randomized control trials will be helpful to make the 
final decision which procedure should be considered in 
candidates for bariatric treatment.
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